Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.7 |
mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.025 | 0.7 |
mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.7 |
mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.023 | 0.7 |
mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |